Pregnancy, baby, and childhood outcomes from using anti-seizure medication during pregnancy.

ABSTRACT:

Background

Evidence of the safety of some anti-seizure medicines (ASMs) during pregnancy remains uncertain.

Methods

We conducted a population-based cohort study of singleton pregnancies in Scotland conceived between 01/04/2010-02/07/2023. Exposure was 'any ASM' prescription issued 28 days prior to conception up to pregnancy end. Seven monotherapies were also examined: valproate, topiramate, carbamazepine, lamotrigine, levetiracetam, gabapentin and pregabalin. Unexposed comparators were matched to the exposed on gestational age and year of conception. Pregnancy loss, congenital condition and child development outcomes were compared by exposure status using conditional logistic regression to account for the matched study design.

Results

Here we show pregnancy loss (3175

SUBMITTER: Moore E 

PROVIDER: S-EPMC12808125 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature